Sort   by:  
 Page size 
UnknownBasic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.
Not available
S-EPMC3828005 | biostudies-literature
UnknownPBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profile.
Not available
S-EPMC10196439 | biostudies-literature
UnknownIncreasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations.
Not available
S-EPMC8923731 | biostudies-literature
UnknownPhysiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
Not available
S-EPMC7020312 | biostudies-literature
UnknownTowards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6.
Not available
S-EPMC4961080 | biostudies-literature
UnknownRisk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.
Not available
S-EPMC6282492 | biostudies-literature
UnknownUsing PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women.
Not available
S-EPMC11578129 | biostudies-literature
UnknownPrediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator.
Not available
S-EPMC9286715 | biostudies-literature
UnknownImpact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
Not available
S-EPMC7323312 | biostudies-literature
UnknownPrediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model.
Not available
S-EPMC4885489 | biostudies-literature
Sort   by:  
 Page size